| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 25 | 2023 | 1415 | 1.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 65 | 2018 | 11524 | 1.080 |
Why?
|
| Leukemia, Myeloid | 17 | 2005 | 707 | 0.870 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2016 | 1519 | 0.740 |
Why?
|
| Bone Marrow Transplantation | 30 | 2005 | 2765 | 0.680 |
Why?
|
| Leukemia, Myeloid, Acute | 29 | 2012 | 3523 | 0.600 |
Why?
|
| Dacryocystitis | 1 | 2016 | 70 | 0.530 |
Why?
|
| Vincristine | 31 | 2014 | 1039 | 0.500 |
Why?
|
| Burkitt Lymphoma | 7 | 2018 | 327 | 0.460 |
Why?
|
| Cytarabine | 23 | 2014 | 692 | 0.440 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2016 | 523 | 0.430 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 169 | 0.430 |
Why?
|
| Idarubicin | 1 | 2012 | 62 | 0.420 |
Why?
|
| Doxorubicin | 29 | 2014 | 2234 | 0.410 |
Why?
|
| Diazepam | 1 | 2012 | 205 | 0.390 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2016 | 570 | 0.360 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 2023 | 1381 | 0.350 |
Why?
|
| Leukemia | 10 | 2004 | 1511 | 0.350 |
Why?
|
| Prednisone | 20 | 2014 | 1574 | 0.330 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 4 | 2012 | 48 | 0.320 |
Why?
|
| Child | 119 | 2021 | 77709 | 0.310 |
Why?
|
| Child, Preschool | 85 | 2019 | 41006 | 0.300 |
Why?
|
| Lymphoma, B-Cell | 4 | 2018 | 931 | 0.300 |
Why?
|
| Adolescent | 102 | 2019 | 85781 | 0.290 |
Why?
|
| Disease-Free Survival | 20 | 2014 | 6895 | 0.280 |
Why?
|
| Antineoplastic Protocols | 2 | 2005 | 50 | 0.280 |
Why?
|
| Methotrexate | 13 | 2014 | 1727 | 0.270 |
Why?
|
| Benzodiazepines | 1 | 2012 | 1101 | 0.270 |
Why?
|
| Down Syndrome | 9 | 2012 | 880 | 0.260 |
Why?
|
| Chernobyl Nuclear Accident | 1 | 2004 | 15 | 0.260 |
Why?
|
| Remission Induction | 20 | 2014 | 2386 | 0.250 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2018 | 895 | 0.240 |
Why?
|
| Daunorubicin | 10 | 2012 | 158 | 0.240 |
Why?
|
| Mediastinal Neoplasms | 10 | 1995 | 423 | 0.240 |
Why?
|
| Etoposide | 9 | 2014 | 641 | 0.230 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2007 | 342 | 0.230 |
Why?
|
| Lymphoma | 9 | 1999 | 1877 | 0.220 |
Why?
|
| Vinblastine | 6 | 2014 | 502 | 0.220 |
Why?
|
| Neoplasm Staging | 23 | 2014 | 11031 | 0.210 |
Why?
|
| Harringtonines | 1 | 2001 | 8 | 0.210 |
Why?
|
| Combined Modality Therapy | 24 | 2008 | 8642 | 0.190 |
Why?
|
| Cyclophosphamide | 12 | 2014 | 2242 | 0.180 |
Why?
|
| Prognosis | 29 | 2023 | 29063 | 0.180 |
Why?
|
| Exercise Test | 1 | 2007 | 2074 | 0.170 |
Why?
|
| Infant | 45 | 2014 | 35136 | 0.170 |
Why?
|
| Chromosome Aberrations | 8 | 2000 | 1813 | 0.170 |
Why?
|
| Procarbazine | 7 | 2004 | 181 | 0.170 |
Why?
|
| Leukemia, Lymphoid | 7 | 1988 | 315 | 0.170 |
Why?
|
| Whole-Body Irradiation | 3 | 1998 | 449 | 0.170 |
Why?
|
| Myeloproliferative Disorders | 3 | 2017 | 606 | 0.160 |
Why?
|
| Recurrence | 18 | 2013 | 8340 | 0.160 |
Why?
|
| Splenomegaly | 2 | 2017 | 190 | 0.150 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2001 | 624 | 0.150 |
Why?
|
| Acute Disease | 18 | 2005 | 7149 | 0.150 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1999 | 255 | 0.150 |
Why?
|
| STAT Transcription Factors | 1 | 2017 | 182 | 0.150 |
Why?
|
| Survival Rate | 17 | 2014 | 12788 | 0.140 |
Why?
|
| Janus Kinases | 1 | 2017 | 244 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2014 | 693 | 0.140 |
Why?
|
| Lymphoma, Follicular | 2 | 2012 | 435 | 0.140 |
Why?
|
| Male | 94 | 2021 | 350118 | 0.140 |
Why?
|
| Humans | 153 | 2023 | 744343 | 0.140 |
Why?
|
| Drug Administration Schedule | 11 | 2014 | 4933 | 0.130 |
Why?
|
| Survival Analysis | 15 | 2010 | 10252 | 0.130 |
Why?
|
| Thioguanine | 4 | 2000 | 46 | 0.130 |
Why?
|
| Critical Pathways | 1 | 2019 | 476 | 0.130 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2009 | 236 | 0.130 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2017 | 434 | 0.120 |
Why?
|
| Antineoplastic Agents | 15 | 2003 | 13695 | 0.120 |
Why?
|
| Neuroblastoma | 3 | 2000 | 1226 | 0.120 |
Why?
|
| Female | 95 | 2021 | 380194 | 0.120 |
Why?
|
| Tretinoin | 3 | 2009 | 517 | 0.120 |
Why?
|
| Abdominal Neoplasms | 3 | 1992 | 292 | 0.120 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2005 | 1378 | 0.120 |
Why?
|
| Length of Stay | 1 | 2007 | 6309 | 0.120 |
Why?
|
| Treatment Outcome | 29 | 2018 | 63114 | 0.110 |
Why?
|
| Nervous System Neoplasms | 3 | 1990 | 91 | 0.110 |
Why?
|
| Neutropenia | 5 | 2012 | 895 | 0.110 |
Why?
|
| Haemophilus Vaccines | 4 | 1997 | 69 | 0.110 |
Why?
|
| Leukocyte Count | 8 | 2006 | 1588 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 21 | 2 | 2006 | 230 | 0.110 |
Why?
|
| Cyclosporine | 3 | 2005 | 786 | 0.110 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1999 | 1320 | 0.100 |
Why?
|
| Prednisolone | 8 | 2001 | 334 | 0.100 |
Why?
|
| Gene Rearrangement | 2 | 2012 | 1179 | 0.100 |
Why?
|
| Adult | 57 | 2021 | 214055 | 0.100 |
Why?
|
| Salvage Therapy | 4 | 2010 | 1275 | 0.100 |
Why?
|
| Neoplasm, Residual | 2 | 2015 | 973 | 0.100 |
Why?
|
| Outpatients | 1 | 2019 | 1486 | 0.100 |
Why?
|
| Life Tables | 5 | 2002 | 370 | 0.100 |
Why?
|
| Cyclosporins | 1 | 2010 | 220 | 0.090 |
Why?
|
| Core Binding Factors | 1 | 2010 | 31 | 0.090 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1990 | 39 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2012 | 1434 | 0.090 |
Why?
|
| Immunophenotyping | 5 | 2012 | 1880 | 0.090 |
Why?
|
| Caregivers | 1 | 2021 | 2094 | 0.090 |
Why?
|
| Infusions, Intravenous | 6 | 2014 | 2274 | 0.090 |
Why?
|
| Mitoxantrone | 3 | 2010 | 152 | 0.090 |
Why?
|
| Immunotherapy, Active | 3 | 1998 | 60 | 0.080 |
Why?
|
| Myelodysplastic Syndromes | 5 | 1997 | 1352 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 4 | 2003 | 1677 | 0.080 |
Why?
|
| Leukemia, B-Cell | 1 | 2009 | 86 | 0.080 |
Why?
|
| Health Expenditures | 1 | 2021 | 2348 | 0.080 |
Why?
|
| Graft vs Host Disease | 8 | 1997 | 2957 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2012 | 9239 | 0.080 |
Why?
|
| Injections, Spinal | 3 | 2018 | 303 | 0.080 |
Why?
|
| Follow-Up Studies | 17 | 2014 | 39050 | 0.080 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 1988 | 30 | 0.080 |
Why?
|
| Infant, Newborn | 15 | 2012 | 25625 | 0.080 |
Why?
|
| Drug Resistance, Multiple | 3 | 2010 | 252 | 0.080 |
Why?
|
| Anemia, Hemolytic | 1 | 1988 | 168 | 0.070 |
Why?
|
| Inpatients | 1 | 2019 | 2518 | 0.070 |
Why?
|
| Kidney Diseases | 2 | 1988 | 2149 | 0.070 |
Why?
|
| Azacitidine | 2 | 2000 | 347 | 0.070 |
Why?
|
| Trachea | 2 | 1995 | 1076 | 0.070 |
Why?
|
| Echocardiography, Stress | 1 | 2006 | 131 | 0.070 |
Why?
|
| Bone Neoplasms | 4 | 1999 | 2529 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2010 | 776 | 0.070 |
Why?
|
| Mosaicism | 2 | 2006 | 441 | 0.070 |
Why?
|
| Lung Neoplasms | 3 | 2007 | 13102 | 0.070 |
Why?
|
| Leukocytosis | 2 | 2003 | 247 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2002 | 2618 | 0.060 |
Why?
|
| Karyotyping | 6 | 2005 | 1243 | 0.060 |
Why?
|
| Republic of Belarus | 1 | 2004 | 38 | 0.060 |
Why?
|
| Plasmacytoma | 1 | 1985 | 183 | 0.060 |
Why?
|
| Forced Expiratory Volume | 2 | 2007 | 1743 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 3 | 1988 | 1363 | 0.060 |
Why?
|
| Bone Marrow | 7 | 2014 | 2948 | 0.060 |
Why?
|
| Chromosomes, Human, 16-18 | 1 | 1984 | 32 | 0.060 |
Why?
|
| Ukraine | 1 | 2004 | 111 | 0.060 |
Why?
|
| Trisomy | 1 | 2006 | 266 | 0.060 |
Why?
|
| GATA1 Transcription Factor | 1 | 2005 | 293 | 0.060 |
Why?
|
| Histological Techniques | 1 | 2004 | 198 | 0.060 |
Why?
|
| Radiotherapy Dosage | 5 | 2002 | 2879 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1998 | 903 | 0.060 |
Why?
|
| Young Adult | 8 | 2014 | 56430 | 0.060 |
Why?
|
| Russia | 1 | 2004 | 408 | 0.060 |
Why?
|
| Lung Diseases | 3 | 2002 | 1886 | 0.060 |
Why?
|
| Fibrosarcoma | 1 | 1985 | 348 | 0.060 |
Why?
|
| Bone Marrow Examination | 2 | 2003 | 157 | 0.060 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2002 | 27 | 0.060 |
Why?
|
| Leukemia, Radiation-Induced | 3 | 1998 | 40 | 0.060 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 1985 | 286 | 0.050 |
Why?
|
| Mechlorethamine | 5 | 1993 | 136 | 0.050 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2004 | 214 | 0.050 |
Why?
|
| Radiotherapy | 3 | 1990 | 1533 | 0.050 |
Why?
|
| Antibodies, Bacterial | 3 | 1997 | 1470 | 0.050 |
Why?
|
| Pediatrics | 1 | 2017 | 3475 | 0.050 |
Why?
|
| Tetanus Toxoid | 3 | 1997 | 193 | 0.050 |
Why?
|
| Lymph Nodes | 3 | 2012 | 3474 | 0.050 |
Why?
|
| Vomiting | 2 | 2012 | 636 | 0.050 |
Why?
|
| Cranial Irradiation | 2 | 1997 | 401 | 0.050 |
Why?
|
| Pneumonectomy | 2 | 2007 | 1094 | 0.050 |
Why?
|
| Chromosome Disorders | 2 | 2000 | 514 | 0.050 |
Why?
|
| Translocation, Genetic | 3 | 2010 | 1420 | 0.050 |
Why?
|
| Transplantation, Autologous | 5 | 1997 | 2124 | 0.050 |
Why?
|
| Disease Progression | 4 | 2012 | 13284 | 0.050 |
Why?
|
| Genes, MDR | 1 | 2000 | 37 | 0.050 |
Why?
|
| Mediastinum | 3 | 1986 | 267 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2002 | 1770 | 0.050 |
Why?
|
| Cancer Vaccines | 2 | 1998 | 1023 | 0.050 |
Why?
|
| Drug Therapy, Combination | 11 | 1997 | 6489 | 0.040 |
Why?
|
| Chromosome Inversion | 1 | 2000 | 127 | 0.040 |
Why?
|
| Pericardial Effusion | 1 | 2002 | 247 | 0.040 |
Why?
|
| Rhabdomyosarcoma | 3 | 1990 | 382 | 0.040 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2003 | 233 | 0.040 |
Why?
|
| Retrospective Studies | 16 | 2017 | 77449 | 0.040 |
Why?
|
| Hospitalization | 1 | 2019 | 10262 | 0.040 |
Why?
|
| Eosinophils | 1 | 1984 | 955 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2008 | 2016 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 5 | 1996 | 3386 | 0.040 |
Why?
|
| Neoplasms | 3 | 2021 | 21683 | 0.040 |
Why?
|
| Fever of Unknown Origin | 1 | 2019 | 93 | 0.040 |
Why?
|
| Vaccines, Conjugate | 2 | 1997 | 333 | 0.040 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 1999 | 140 | 0.040 |
Why?
|
| Risk Factors | 8 | 2007 | 72290 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 1999 | 640 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 2 | 1996 | 2538 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2002 | 1850 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 7659 | 0.040 |
Why?
|
| Chromosomes, Human | 1 | 2000 | 457 | 0.040 |
Why?
|
| Perphenazine | 1 | 1997 | 34 | 0.040 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2003 | 685 | 0.040 |
Why?
|
| Immunotherapy, Adoptive | 2 | 1997 | 1270 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 2 | 2007 | 2734 | 0.040 |
Why?
|
| Diphenhydramine | 1 | 1997 | 63 | 0.040 |
Why?
|
| Diaphragm | 2 | 1990 | 349 | 0.040 |
Why?
|
| HL-60 Cells | 1 | 1998 | 365 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1999 | 456 | 0.040 |
Why?
|
| Antigens, Surface | 4 | 1992 | 1663 | 0.040 |
Why?
|
| Haemophilus influenzae | 1 | 1997 | 171 | 0.040 |
Why?
|
| Leukemic Infiltration | 1 | 1997 | 48 | 0.040 |
Why?
|
| Ondansetron | 1 | 1997 | 90 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2002 | 3479 | 0.040 |
Why?
|
| Electrocardiography | 2 | 2007 | 6442 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 1998 | 2085 | 0.040 |
Why?
|
| Amsacrine | 1 | 1996 | 18 | 0.040 |
Why?
|
| Uganda | 1 | 2021 | 1243 | 0.040 |
Why?
|
| Dopamine Antagonists | 1 | 1997 | 296 | 0.040 |
Why?
|
| Hydromorphone | 1 | 1996 | 65 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2004 | 1660 | 0.040 |
Why?
|
| Middle Aged | 27 | 2012 | 213383 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2012 | 10481 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2001 | 5172 | 0.030 |
Why?
|
| Laparotomy | 3 | 1994 | 473 | 0.030 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 1996 | 109 | 0.030 |
Why?
|
| Haemophilus Infections | 1 | 1996 | 95 | 0.030 |
Why?
|
| Mucopolysaccharidosis I | 1 | 1996 | 50 | 0.030 |
Why?
|
| Antiemetics | 1 | 1997 | 177 | 0.030 |
Why?
|
| Leukemia, Experimental | 1 | 1996 | 246 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2000 | 5442 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 6538 | 0.030 |
Why?
|
| Age Factors | 6 | 2005 | 18370 | 0.030 |
Why?
|
| Clone Cells | 2 | 1995 | 1692 | 0.030 |
Why?
|
| Teratoma | 2 | 1991 | 395 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1999 | 692 | 0.030 |
Why?
|
| Antigens, Neoplasm | 5 | 1992 | 1988 | 0.030 |
Why?
|
| Meninges | 1 | 1997 | 190 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1999 | 1950 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2006 | 8428 | 0.030 |
Why?
|
| Typhlitis | 1 | 2014 | 2 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 4 | 1997 | 1681 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2017 | 629 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 5 | 2009 | 9274 | 0.030 |
Why?
|
| Dactinomycin | 4 | 1999 | 318 | 0.030 |
Why?
|
| Polysaccharides, Bacterial | 2 | 1996 | 578 | 0.030 |
Why?
|
| Graft Survival | 5 | 1996 | 3737 | 0.030 |
Why?
|
| Blast Crisis | 2 | 2006 | 103 | 0.030 |
Why?
|
| Research Report | 1 | 2017 | 355 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2017 | 23403 | 0.030 |
Why?
|
| Actuarial Analysis | 3 | 1990 | 378 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2000 | 6365 | 0.030 |
Why?
|
| Sialoglycoproteins | 1 | 1994 | 318 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1994 | 262 | 0.030 |
Why?
|
| Granulocytes | 3 | 1992 | 548 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2001 | 1179 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2005 | 10943 | 0.030 |
Why?
|
| Lung | 2 | 1995 | 9856 | 0.030 |
Why?
|
| Genes, myc | 1 | 2014 | 399 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 1996 | 673 | 0.030 |
Why?
|
| Lymphokines | 2 | 1997 | 949 | 0.030 |
Why?
|
| Cell Separation | 2 | 1996 | 1751 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2021 | 2682 | 0.030 |
Why?
|
| Aged | 12 | 2012 | 163280 | 0.030 |
Why?
|
| Biopsy | 3 | 2003 | 6756 | 0.030 |
Why?
|
| Morphine | 1 | 1996 | 657 | 0.030 |
Why?
|
| Leukocytes | 2 | 1999 | 2043 | 0.030 |
Why?
|
| Blood Transfusion | 3 | 1988 | 1301 | 0.030 |
Why?
|
| Pilot Projects | 3 | 2015 | 8324 | 0.030 |
Why?
|
| Mutation | 4 | 2010 | 29786 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2000 | 5974 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 6234 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2006 | 15076 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 4554 | 0.030 |
Why?
|
| Sarcoma | 2 | 1988 | 1897 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2012 | 295 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2003 | 2133 | 0.030 |
Why?
|
| Time Factors | 12 | 2001 | 40075 | 0.020 |
Why?
|
| Anthracyclines | 1 | 2013 | 288 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2004 | 23338 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2001 | 4026 | 0.020 |
Why?
|
| Immunotherapy | 2 | 2018 | 4445 | 0.020 |
Why?
|
| Mothers | 1 | 2021 | 2165 | 0.020 |
Why?
|
| Asparaginase | 1 | 2012 | 236 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 1997 | 1598 | 0.020 |
Why?
|
| Genital Neoplasms, Male | 1 | 1990 | 74 | 0.020 |
Why?
|
| Self Report | 1 | 2021 | 3558 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 1999 | 2133 | 0.020 |
Why?
|
| Carboplatin | 2 | 2009 | 801 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 644 | 0.020 |
Why?
|
| Hypergammaglobulinemia | 1 | 1989 | 74 | 0.020 |
Why?
|
| Tissue Donors | 2 | 1996 | 2240 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1995 | 689 | 0.020 |
Why?
|
| Pigmentation Disorders | 1 | 1990 | 101 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2004 | 21746 | 0.020 |
Why?
|
| DNA Primers | 2 | 2005 | 2892 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 1998 | 1376 | 0.020 |
Why?
|
| Nausea | 1 | 2012 | 673 | 0.020 |
Why?
|
| Multiple Myeloma | 2 | 1994 | 5181 | 0.020 |
Why?
|
| Steroids | 1 | 1994 | 930 | 0.020 |
Why?
|
| Brain Neoplasms | 3 | 2005 | 8863 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 1992 | 470 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 1999 | 1956 | 0.020 |
Why?
|
| Medicine | 1 | 2017 | 946 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 3 | 2005 | 6314 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2012 | 57776 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 2 | 1995 | 1061 | 0.020 |
Why?
|
| Anesthesia, Local | 1 | 1991 | 275 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2002 | 2788 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2009 | 228 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1994 | 1836 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 1988 | 191 | 0.020 |
Why?
|
| Vaccines | 1 | 1997 | 822 | 0.020 |
Why?
|
| Clinical Trials as Topic | 3 | 1999 | 7913 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 9438 | 0.020 |
Why?
|
| Immunoglobulin G | 2 | 1997 | 4560 | 0.020 |
Why?
|
| Cluster Analysis | 2 | 2005 | 2715 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 892 | 0.020 |
Why?
|
| Urogenital Neoplasms | 1 | 1989 | 137 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2000 | 12354 | 0.020 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 1989 | 177 | 0.020 |
Why?
|
| Genes, ras | 1 | 1990 | 690 | 0.020 |
Why?
|
| Immunoglobulin A | 2 | 1994 | 992 | 0.020 |
Why?
|
| Monosomy | 1 | 1986 | 54 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1996 | 2540 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 1998 | 3768 | 0.020 |
Why?
|
| United States | 7 | 2003 | 69872 | 0.020 |
Why?
|
| Mediastinal Emphysema | 1 | 1986 | 31 | 0.020 |
Why?
|
| Thoracic Neoplasms | 1 | 1989 | 268 | 0.020 |
Why?
|
| Bacterial Infections | 3 | 2003 | 1401 | 0.020 |
Why?
|
| Immunosuppressive Agents | 4 | 2005 | 4149 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 4 | 2002 | 6171 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 19905 | 0.020 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1990 | 547 | 0.020 |
Why?
|
| HLA Antigens | 2 | 1990 | 1381 | 0.020 |
Why?
|
| Risk | 4 | 1987 | 9687 | 0.020 |
Why?
|
| Mitolactol | 1 | 2005 | 13 | 0.020 |
Why?
|
| Transplantation, Homologous | 4 | 1996 | 4776 | 0.020 |
Why?
|
| Neoplasm Metastasis | 4 | 2001 | 4851 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 5 | 1995 | 20129 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2005 | 3920 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 2649 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2727 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1986 | 322 | 0.020 |
Why?
|
| Neuralgia | 1 | 2012 | 570 | 0.020 |
Why?
|
| Decision Making | 1 | 2000 | 3887 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2012 | 40561 | 0.020 |
Why?
|
| Neprilysin | 1 | 1988 | 439 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 4751 | 0.020 |
Why?
|
| Cytokines | 2 | 1998 | 7322 | 0.020 |
Why?
|
| Preleukemia | 1 | 1985 | 35 | 0.020 |
Why?
|
| Diagnosis, Differential | 4 | 2007 | 12959 | 0.020 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 1985 | 173 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 1988 | 927 | 0.020 |
Why?
|
| Prospective Studies | 6 | 2012 | 53288 | 0.020 |
Why?
|
| Lung Diseases, Fungal | 1 | 1985 | 122 | 0.020 |
Why?
|
| Bacterial Vaccines | 2 | 1996 | 403 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 1987 | 2924 | 0.020 |
Why?
|
| Enterocolitis | 1 | 1986 | 102 | 0.020 |
Why?
|
| Phosphoglycerate Kinase | 2 | 1995 | 68 | 0.020 |
Why?
|
| Mice, Inbred Strains | 2 | 1998 | 1827 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 1985 | 719 | 0.020 |
Why?
|
| Eye Neoplasms | 1 | 1986 | 313 | 0.020 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2004 | 56 | 0.020 |
Why?
|
| Drug Hypersensitivity | 1 | 1993 | 884 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 1994 | 2072 | 0.020 |
Why?
|
| Enzymes | 1 | 2006 | 266 | 0.020 |
Why?
|
| Chromosome Banding | 1 | 1984 | 278 | 0.020 |
Why?
|
| Bilirubin | 1 | 2006 | 425 | 0.010 |
Why?
|
| Retinoblastoma | 1 | 1986 | 318 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2005 | 1375 | 0.010 |
Why?
|
| Radiography | 2 | 1986 | 7023 | 0.010 |
Why?
|
| Exons | 1 | 2010 | 2437 | 0.010 |
Why?
|
| Erythropoiesis | 1 | 1988 | 705 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1983 | 101 | 0.010 |
Why?
|
| Luciferases | 1 | 2005 | 733 | 0.010 |
Why?
|
| Anesthesia, General | 1 | 1991 | 1171 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2000 | 9959 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 1997 | 4479 | 0.010 |
Why?
|
| Particle Accelerators | 1 | 1983 | 173 | 0.010 |
Why?
|
| Methods | 2 | 1988 | 1129 | 0.010 |
Why?
|
| Bronchitis | 1 | 2003 | 201 | 0.010 |
Why?
|
| Immunization | 3 | 1996 | 1256 | 0.010 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1985 | 281 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2007 | 1094 | 0.010 |
Why?
|
| Cardiovascular Diseases | 2 | 2006 | 15165 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1985 | 1799 | 0.010 |
Why?
|
| Bleomycin | 2 | 1993 | 512 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1982 | 419 | 0.010 |
Why?
|
| Reoperation | 1 | 1992 | 4201 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1985 | 2645 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1986 | 1401 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2002 | 380 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 2002 | 163 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 2003 | 277 | 0.010 |
Why?
|
| Lymphography | 2 | 1994 | 201 | 0.010 |
Why?
|
| Cross-Over Studies | 2 | 1997 | 2029 | 0.010 |
Why?
|
| Apoptosis | 1 | 1998 | 9727 | 0.010 |
Why?
|
| Cytoplasmic Granules | 1 | 1984 | 610 | 0.010 |
Why?
|
| Interleukin-4 | 2 | 1998 | 1147 | 0.010 |
Why?
|
| Pain | 1 | 1996 | 4986 | 0.010 |
Why?
|
| Megakaryocytes | 2 | 2002 | 545 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2005 | 981 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1985 | 1539 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1991 | 5078 | 0.010 |
Why?
|
| Remission, Spontaneous | 2 | 1978 | 382 | 0.010 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2004 | 491 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 1994 | 3848 | 0.010 |
Why?
|
| Pregnancy | 2 | 1999 | 29144 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 1996 | 3674 | 0.010 |
Why?
|
| Dacarbazine | 2 | 1993 | 566 | 0.010 |
Why?
|
| Logistic Models | 2 | 2006 | 13408 | 0.010 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1985 | 501 | 0.010 |
Why?
|
| Leukocyte Transfusion | 1 | 1979 | 60 | 0.010 |
Why?
|
| Blood Component Removal | 1 | 2000 | 125 | 0.010 |
Why?
|
| Graft vs Host Reaction | 1 | 1979 | 104 | 0.010 |
Why?
|
| Central Nervous System Diseases | 2 | 1981 | 518 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1980 | 387 | 0.010 |
Why?
|
| DNA Helicases | 1 | 2004 | 859 | 0.010 |
Why?
|
| Benzamides | 1 | 2004 | 1379 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1988 | 2250 | 0.010 |
Why?
|
| Exanthema | 1 | 2003 | 501 | 0.010 |
Why?
|
| Polymorphism, Genetic | 2 | 2002 | 4328 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2002 | 1572 | 0.010 |
Why?
|
| Quality of Life | 1 | 1999 | 12804 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2002 | 1654 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 5892 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 1460 | 0.010 |
Why?
|
| DNA, Neoplasm | 2 | 1994 | 1758 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2006 | 3748 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 1996 | 141 | 0.010 |
Why?
|
| Iduronidase | 1 | 1996 | 31 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1989 | 4665 | 0.010 |
Why?
|
| S Phase | 1 | 1997 | 423 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1997 | 6622 | 0.010 |
Why?
|
| Maximal Expiratory Flow Rate | 1 | 1995 | 44 | 0.010 |
Why?
|
| Platelet Transfusion | 1 | 1979 | 314 | 0.010 |
Why?
|
| Incidence | 2 | 2006 | 20947 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 1997 | 221 | 0.010 |
Why?
|
| Leukapheresis | 1 | 1996 | 131 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 2 | 1990 | 228 | 0.010 |
Why?
|
| Heart Rate | 1 | 2006 | 4091 | 0.010 |
Why?
|
| Leucovorin | 1 | 1977 | 628 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 2460 | 0.010 |
Why?
|
| Bacterial Capsules | 1 | 1996 | 251 | 0.010 |
Why?
|
| Sinusitis | 1 | 2003 | 923 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1997 | 648 | 0.010 |
Why?
|
| Pneumonia | 1 | 1986 | 2133 | 0.010 |
Why?
|
| Kinetics | 1 | 1982 | 6473 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 1983 | 2942 | 0.010 |
Why?
|
| Piperazines | 1 | 2004 | 2488 | 0.010 |
Why?
|
| Dosage Compensation, Genetic | 1 | 1995 | 211 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2006 | 5007 | 0.010 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 1995 | 207 | 0.010 |
Why?
|
| Antibody Formation | 2 | 1994 | 1402 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1994 | 878 | 0.010 |
Why?
|
| Streptococcus pneumoniae | 1 | 1978 | 714 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 1994 | 297 | 0.010 |
Why?
|
| Prevalence | 1 | 2010 | 15226 | 0.010 |
Why?
|
| Kidney | 1 | 1988 | 7186 | 0.010 |
Why?
|
| Animals | 6 | 1998 | 168757 | 0.010 |
Why?
|
| Pneumococcal Vaccines | 1 | 1996 | 391 | 0.010 |
Why?
|
| Anemia, Aplastic | 1 | 1994 | 226 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2003 | 2728 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2004 | 2942 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1991 | 191 | 0.010 |
Why?
|
| Th1 Cells | 1 | 1997 | 1057 | 0.010 |
Why?
|
| Acyclovir | 1 | 1992 | 272 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 1977 | 881 | 0.010 |
Why?
|
| Testicular Neoplasms | 2 | 1989 | 804 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 14722 | 0.010 |
Why?
|
| X Chromosome | 1 | 1995 | 814 | 0.010 |
Why?
|
| Vaccines, Synthetic | 1 | 1994 | 634 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1998 | 3689 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 1995 | 1616 | 0.010 |
Why?
|
| T-Lymphocytes | 3 | 1990 | 10180 | 0.010 |
Why?
|
| Research Design | 1 | 2006 | 5987 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1991 | 821 | 0.010 |
Why?
|
| Probability | 2 | 1990 | 2505 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1986 | 13989 | 0.010 |
Why?
|
| Mice | 4 | 1998 | 81183 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1997 | 1821 | 0.010 |
Why?
|
| Hair Color | 1 | 1990 | 136 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1998 | 1838 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 5853 | 0.010 |
Why?
|
| DNA Probes | 1 | 1990 | 560 | 0.010 |
Why?
|
| Neutrophils | 1 | 2002 | 3719 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1998 | 3772 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1994 | 1537 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 15540 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1983 | 9146 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 1990 | 608 | 0.010 |
Why?
|
| Macrophages | 1 | 1983 | 5655 | 0.010 |
Why?
|
| Receptors, Androgen | 1 | 1995 | 1058 | 0.010 |
Why?
|
| Codon | 1 | 1990 | 611 | 0.010 |
Why?
|
| Orchiectomy | 1 | 1990 | 474 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1994 | 1609 | 0.000 |
Why?
|
| Primary Myelofibrosis | 1 | 1990 | 215 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 17446 | 0.000 |
Why?
|
| Genotype | 1 | 2002 | 12951 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 11366 | 0.000 |
Why?
|
| Diarrhea | 1 | 1994 | 1348 | 0.000 |
Why?
|
| Heterozygote | 1 | 1994 | 2804 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 9648 | 0.000 |
Why?
|
| Pain Measurement | 1 | 1996 | 3420 | 0.000 |
Why?
|
| Dysgerminoma | 1 | 1986 | 65 | 0.000 |
Why?
|
| Colony-Forming Units Assay | 1 | 1986 | 356 | 0.000 |
Why?
|
| Penicillium | 1 | 1985 | 22 | 0.000 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1998 | 4420 | 0.000 |
Why?
|
| Heart Arrest | 1 | 1996 | 1470 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1997 | 5524 | 0.000 |
Why?
|
| Cause of Death | 1 | 1996 | 3584 | 0.000 |
Why?
|
| Leukopenia | 1 | 1985 | 212 | 0.000 |
Why?
|
| Body Weight | 1 | 1996 | 4669 | 0.000 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1989 | 604 | 0.000 |
Why?
|
| Interleukin-2 | 1 | 1991 | 1904 | 0.000 |
Why?
|
| Lymph Node Excision | 1 | 1990 | 1261 | 0.000 |
Why?
|
| Transcription Factors | 1 | 2004 | 12208 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 2006 | 15295 | 0.000 |
Why?
|
| Naphthol AS D Esterase | 1 | 1983 | 14 | 0.000 |
Why?
|
| Cell Division | 1 | 1991 | 4568 | 0.000 |
Why?
|
| Aspergillosis | 1 | 1985 | 235 | 0.000 |
Why?
|
| Syndrome | 1 | 1990 | 3251 | 0.000 |
Why?
|
| Genital Neoplasms, Female | 1 | 1989 | 523 | 0.000 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1985 | 876 | 0.000 |
Why?
|
| Diploidy | 1 | 1983 | 138 | 0.000 |
Why?
|
| Metaphase | 1 | 1983 | 151 | 0.000 |
Why?
|
| Neuropsychological Tests | 1 | 1996 | 6993 | 0.000 |
Why?
|
| Interferon-gamma | 1 | 1991 | 3206 | 0.000 |
Why?
|
| Radiation Injuries | 1 | 1990 | 1180 | 0.000 |
Why?
|
| Candidiasis | 1 | 1985 | 366 | 0.000 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 1990 | 1692 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1996 | 12026 | 0.000 |
Why?
|
| Pedigree | 1 | 1990 | 4644 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1980 | 7181 | 0.000 |
Why?
|
| DNA Mutational Analysis | 1 | 1990 | 4186 | 0.000 |
Why?
|
| Neoplasm Invasiveness | 1 | 1989 | 3616 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1997 | 19229 | 0.000 |
Why?
|
| DNA | 1 | 1995 | 7301 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 35421 | 0.000 |
Why?
|
| Peroxidase | 1 | 1983 | 611 | 0.000 |
Why?
|
| Genetic Markers | 1 | 1986 | 2634 | 0.000 |
Why?
|
| Thyroid Diseases | 1 | 1983 | 379 | 0.000 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1979 | 58 | 0.000 |
Why?
|
| Emergencies | 1 | 1986 | 1170 | 0.000 |
Why?
|
| Horses | 1 | 1980 | 304 | 0.000 |
Why?
|
| Gene Expression | 1 | 1992 | 7799 | 0.000 |
Why?
|
| Sex Factors | 1 | 1993 | 10397 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1994 | 13033 | 0.000 |
Why?
|
| Alleles | 1 | 1990 | 6933 | 0.000 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1983 | 1475 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1997 | 18029 | 0.000 |
Why?
|
| Antilymphocyte Serum | 1 | 1980 | 492 | 0.000 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1986 | 1130 | 0.000 |
Why?
|
| Fever | 1 | 1986 | 1616 | 0.000 |
Why?
|
| Growth Disorders | 1 | 1983 | 645 | 0.000 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1980 | 548 | 0.000 |
Why?
|
| Splenectomy | 1 | 1978 | 395 | 0.000 |
Why?
|
| Inflammation | 1 | 1996 | 10638 | 0.000 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1989 | 2245 | 0.000 |
Why?
|
| Infertility | 1 | 1983 | 655 | 0.000 |
Why?
|
| Bone Marrow Cells | 1 | 1983 | 2513 | 0.000 |
Why?
|
| Phenotype | 2 | 1983 | 16365 | 0.000 |
Why?
|
| Aging | 1 | 1994 | 8664 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1983 | 2617 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1983 | 2455 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 1989 | 11124 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1983 | 11483 | 0.000 |
Why?
|